Mirum Pharmaceuticals Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Net Income	-798.84	-23.36	-87.94	-163.42	-135.67	-83.99
Depreciation & Amortization	25.07	24.24	23.63	10.83	3.24	0.6
Stock-Based Compensation	91.82	71.42	48.44	35.02	27.01	23.09
Other Adjustments	417.18	3.24	3.6	65.84	6.33	-89.44
Change in Receivables	-44.11	-48.06	-11.43	-43.97	-20.73	-
Changes in Inventories	-7.7	-8.45	-3.17	-0.97	-3.44	-0.5
Changes in Accrued Expenses	95.61	50.1	40.31	30.78	7.63	22.92
Changes in Other Operating Activities	50	-13.32	-3.13	-5.05	-4.51	-5.18
Operating Cash Flow	-170.98	55.83	10.33	-70.94	-120.14	-132.76
Operating Cash Flow Growth	-	440.70%	-	-	-	-
Capital Expenditures	-1.58	-0.95	-0.99	-0.11	-0.28	-0.02
Purchases of Intangible Assets	-30	-20	-20	-	-	-19
Purchases of Investments	-98.7	-97.43	-89.03	-27.33	-132.32	-198.03
Proceeds from Sale of Investments	90.88	74.43	19.89	153	140.3	157.6
Payments for Business Acquisitions	-	-	-	-212.76	-	-
Other Investing Activities	-	-	-	-	-	108
Investing Cash Flow	-19.39	-23.95	-90.13	-107.2	7.7	48.55
Long-Term Debt Issued	-	-	-	305.3	-	-
Net Long-Term Debt Issued (Repaid)	-	-	-	305.3	-	-
Issuance of Common Stock	303.86	40.14	17.7	227.15	114.64	9.01
Net Common Stock Issued (Repurchased)	303.86	40.14	17.7	227.15	114.64	9.01
Other Financing Activities	-	-	-	-195.86	-5.55	64.45
Financing Cash Flow	303.86	40.14	17.7	336.6	109.09	73.47
Effect of Exchange Rate Changes on Cash and Cash Equivalents	0.9	3.22	-1.3	-0.13	0.01	-
Net Cash Flow	114.39	75.24	-63.4	158.32	-3.34	-10.75
Free Cash Flow	-172.55	54.87	9.33	-71.05	-120.41	-132.78
Free Cash Flow Growth	-	488.01%	-	-	-	-
FCF Margin	-42.11%	10.53%	2.77%	-38.12%	-156.26%	-693.81%
Free Cash Flow Per Share	-3.18	1.09	0.20	-1.74	-3.54	-4.38
Levered Free Cash Flow	-637.44	28.27	-31.29	177.36	-133.03	-66.17
Unlevered Free Cash Flow	-636.4	27.49	-31.99	-74.35	-122.67	-155.67

SEC Filings: 10-K · 10-Q